80
Participants
Start Date
October 31, 2001
Primary Completion Date
August 31, 2008
Study Completion Date
January 31, 2009
carboplatin
Patients receive carboplatin IV over 15-30 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
irinotecan
Patients receive irinotecan hydrochloride IV over 90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
University of California Davis Cancer Center, Sacramento
Collaborators (1)
National Cancer Institute (NCI)
NIH
Pfizer
INDUSTRY
University of California, Davis
OTHER